GP FAQs

If you are aware that your BOPPP patient has had an untoward medical event, please do the following:

1. Contact the patients Hepatology consultant and or/ BOPPP research team at the Hospital they are being treated for their liver disease using the contact information in the Participant Information Sheet that you were sent when your patient consented to take part.
2. Alternatively, if the above contact details are not obtainable – email kch-tr.boppptrial@nhs.net to inform the central trial management team that an adverse event has been identified, so they can inform the BOPPP research team involved on your behalf.
3. Remind your patient to contact the BOPPP research nurse.

Note – in the event that an adverse event needs to be followed up through to a conclusion, the Hospital treating your patients liver disease may need medical information from you to ensure that the severity of the event and relationship to the trial medication is assessed accordingly.

• Your patient will receive either 6.25 mg or 12.5 mg Carvedilol or placebo (one or two tablets of either). The maximum does is two tablets daily – or 12.5 mg Carvedilol or placebo.
• If preferred, your patient may take their dose OD or BD.

Link to summary of the BOPPP trial

Link to BOPPP Trial Protocol

If you are aware that your BOPPP patient has had an untoward medical event, please do the following:

1. Contact the patients Hepatology consultant and or/ BOPPP research team at the Hospital they are being treated for their liver disease using the contact information in the Participant Information Sheet that you were sent when your patient consented to take part.
2. Alternatively, if the above contact details are not obtainable – email kch-tr.boppptrial@nhs.net to inform the central trial management team that an adverse event has been identified, so they can inform the BOPPP research team involved on your behalf.
3. Remind your patient to contact the BOPPP research nurse.

Note – in the event that an adverse event needs to be followed up through to a conclusion, the Hospital treating your patients liver disease may need medical information from you to ensure that the severity of the event and relationship to the trial medication is assessed accordingly.

• Your patient will receive either 6.25 mg or 12.5 mg Carvedilol or placebo (one or two tablets of either). The maximum does is two tablets daily – or 12.5 mg Carvedilol or placebo.
• If preferred, your patient may take their dose OD or BD.

Link to summary of the BOPPP trial

Link to BOPPP Trial Protocol

If you are aware that your BOPPP patient has had an untoward medical event, please do the following:

1. Contact the patients Hepatology consultant and or/ BOPPP research team at the Hospital they are being treated for their liver disease using the contact information in the Participant Information Sheet that you were sent when your patient consented to take part.
2. Alternatively, if the above contact details are not obtainable – email kch-tr.boppptrial@nhs.net to inform the central trial management team that an adverse event has been identified, so they can inform the BOPPP research team involved on your behalf.
3. Remind your patient to contact the BOPPP research nurse.

Note – in the event that an adverse event needs to be followed up through to a conclusion, the Hospital treating your patients liver disease may need medical information from you to ensure that the severity of the event and relationship to the trial medication is assessed accordingly.

• Your patient will receive either 6.25 mg or 12.5 mg Carvedilol or placebo (one or two tablets of either). The maximum does is two tablets daily – or 12.5 mg Carvedilol or placebo.
• If preferred, your patient may take their dose OD or BD.

Link to summary of the BOPPP trial

Link to BOPPP Trial Protocol

If you are aware that your BOPPP patient has had an untoward medical event, please do the following:

1. Contact the patients Hepatology consultant and or/ BOPPP research team at the Hospital they are being treated for their liver disease using the contact information in the Participant Information Sheet that you were sent when your patient consented to take part.
2. Alternatively, if the above contact details are not obtainable – email kch-tr.boppptrial@nhs.net to inform the central trial management team that an adverse event has been identified, so they can inform the BOPPP research team involved on your behalf.
3. Remind your patient to contact the BOPPP research nurse.

Note – in the event that an adverse event needs to be followed up through to a conclusion, the Hospital treating your patients liver disease may need medical information from you to ensure that the severity of the event and relationship to the trial medication is assessed accordingly.

• Your patient will receive either 6.25 mg or 12.5 mg Carvedilol or placebo (one or two tablets of either). The maximum does is two tablets daily – or 12.5 mg Carvedilol or placebo.
• If preferred, your patient may take their dose OD or BD.

Link to summary of the BOPPP trial

Link to BOPPP Trial Protocol